The RheumNow Week in Review – 4 August 2017 Save

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com. 

1. Amgen submitted its Biologic Licence application to the FDA for Denosumab in Rx of Glucorticoid induced Osteoporosis https://t.co/MdKOssFggV
2. 165 scleroderma pts double pos for centromere & anti–IFI-16 Abs incr. risk for digital vascular events, >3 fold higher odds of Severe Raynauds https://t.co/ueOuUC7R2O  
3. IBD clinic study shows CT-Dx sacroiliitis found in 15% of 233 Crohns, 16.9%, of 83 UC pts & 5.6% 108 controls https://t.co/O2WuJoUPL6
4. Among 608 SSc pts 3% developed Scl renal crisis - risk w/ digital gangrene, pred >15, alb <3, cardiac involvement https://t.co/R6HpDSbk3R
5. Hospitalizationsfor Serious infections increased from 90 to 206  per 100,000 PY from 1993-2013. Sepsis tripled. But pneumonia, UTI & OIs decreased https://t.co/rHL5pJHMSc
6. No Increase in Malformations with Etanercept Use During Pregnancy
7. Lupus Hospitalizations are Common 
8. Arthritis Advisory Panel Votes Down Sirukumab  
9. FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis